Active, Not Recruiting
An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC - CA209-171
Updated: 17 June, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - ECOG Status: PS 0-1 & PS 2 - Subjects with histologically or cytologically-documented SqNSCLC - Subjects must have experienced disease progression or recurrence during or after one prior platinum doublet-based chemotherapy regimen - Subjects must have evaluable disease by CT or MRI per RECIST 1.1 criteria - Subjects with treated or asymptomatic CNS metastases - Prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration - Prior lines of antineoplastic therapy, including hemotherapy, hormonal therapy, immunotherapy, surgical resection of lesions, non-palliative radiation therapy, or standard or investigational agents for treatment of NSCLC, must be completed 28 days prior to the first dose of nivolumab - Males and Females, ages 18 or older Exclusion Criteria: - Subjects with untreated, symptomatic CNS metastases - Subjects with carcinomatous meningitis - Subjects with active, known or suspected autoimmune disease. - Subjects who received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways) or who have previously taken part in a randomized BMS clinical trial for nivolumab or ipilimumab.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information